Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
Shai Shimony(Twitter (United States)), Maximilian Stahl(Harvard University), Jorge Ramos Perez(The University of Texas MD Anderson Cancer Center), Evan C. Chen(Dana-Farber Cancer Institute), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Brian Ball(City Of Hope National Medical Center), Eva J. Schaefer(Dana-Farber Cancer Institute), Guido Marcucci(City of Hope), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Amer M. Zeidan(Yale Cancer Center), Richard M. Stone(Dana-Farber Cancer Institute), R. Coleman Lindsley(Harvard University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Rory M. Shallis(Smilow Cancer Hospital), Donna Neuberg(Otsuka (Japan)), Yiwen Liu(University of Arizona), Anthony S. Stein(University of Hohenheim)
Cited by 30
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k